Among them, a patent filed in 2011 highlighted that the hybrid, combining the two dietary compounds, curcumin and β-ionone, can be used as a bifunctional antiandrogen and multi-targeting agent in both hormone-sensitive (LNCAP) and hormone-independent (22Rv1) prostate cancer cells by inhibiting androgen receptor (AR) signaling and IκB kinases [106]. The gene discussed is AR; the disease is prostate carcinoma.